All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Efineptakin alfa,Immunoglobulin G1
Therapeutic Area: Oncology Product Name: NT-I7
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: NeoImmuneTech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 21, 2020
Details:
This new master agreement will focus initially on a Phase 2 trial in previously untreated, PD-L1-expressing, locally advanced or metastatic non-small cell lung cancer patients, with the goal to evaluate anti-tumor efficacy and safety of the NT-I7 and atezolizumab combination.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tenalisib
Therapeutic Area: Oncology Product Name: RP6530
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Curon Biopharmaceutical
Deal Size: $149.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 12, 2020
Details:
Curon obtains the exclusive development and commercialization rights of Tenalisib for Greater China across all oncology indications, and will lead the clinical development in that territory.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Derazantinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2020
Details:
FGFR inhibitors, including derazantinib, have showed clinical antitumor activity in patients with FGFR2 gene fusion-positive iCCA. To date there is limited clinical evidence for the benefit of FGFR inhibitors in iCCA patients with FGFR2 gene mutations and amplifications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Derazantinib
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 20, 2020
Details:
The FIDES-01 study is a multi-center, open-label phase 2 registrational study of once-daily oral derazantinib for the treatment of patients with inoperable or advanced iCCA and FGFR2 gene fusions or FGFR2 gene mutations or amplifications.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Camidanlumab Tesirine
Therapeutic Area: Oncology Product Name: ADCT-301
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2020
Details:
U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami, formerly ADCT-301) in patients with relapsed or refractory Hodgkin lymphoma (HL).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Loncastuximab Tesirine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2020
Details:
Interim results of the Phase 1/2 trial of Lonca in combination with ibrutinib show an encouraging overall response rate of 75.0% and complete response rate of 58.3% at the recommended Phase 2 Lonca dose.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Loncastuximab Tesirine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2020
Details:
Updated interim data from the pivotal Phase 2 trial of Lonca in patients with relapsed or refactory diffuse large B-cell lymphoma as well as interim results of a Phase 1/2 trial highlighting the potential to advance Lonca into earlier lines of therapy in combination therapies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Loncastuximab Tesirine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2020
Details:
Interim results of pivotal Phase 2 trial reinforce potential of Lonca to become a key part of the treatment paradigm for patients with relapsed or refractory diffuse large B-cell lymphoma.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pracinostat,Azacitidine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2020
Details:
New data from the Phase 2 study evaluating pracinostat in combination with azacitidine in patients with very-high risk myelodysplastic syndromes, will be featured in the ASCO 2020 conference.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Loncastuximab Tesirine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering April 28, 2020
Details:
ADC Therapeutics company is developing antibody drug conjugates, cancer drugs that link a tumor-targeting antibody to a cancer-killing chemical compound.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
